Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced that the Ministry of Health, Labour and Welfare of Japan has approved Tecentriq (atezolizumab) for the treatment of unresectable alveolar soft part sarcoma. This marks the first approval of an immune checkpoint inhibitor in Japan for this specific indication.
Drug Profile
Tecentriq, an anti-PD-L1 monoclonal antibody (mAb), has been approved in Japan for four indications since its initial approval in April 2018, including extensive small cell lung cancer, non-small cell lung cancer, breast cancer, and hepatocellular carcinoma. The latest approval is based on positive results from the Phase II ALBERT study in Japan and a Phase II study in the US, both of which demonstrated the drug’s efficacy and safety in patients with unresectable alveolar soft part sarcoma.-Fineline Info & Tech
Leave a Reply